Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation

doi:10.4240/wjgs.v18.i3.114569

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(34)

(29)

(0)

(497)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Mar 27, 2026; 18(3): 114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569

Table 1 Baseline characteristics of the study groups, n (%)

Data	Control group (n = 60)	Research group (n = 64)	χ²/t	P value
Sex			0.719	0.396
Male	33 (55.00)	40 (62.50)
Female	27 (45.00)	24 (37.50)
Age (years)	54.62 ± 7.11	54.27 ± 7.73	0.262	0.794
Weight (kg)	61.50 ± 8.78	59.83 ± 9.38	1.022	0.309
Illness duration (months)	9.05 ± 1.66	9.17 ± 2.33	0.328	0.743
Clinical staging			0.440	0.507
II	20 (33.33)	25 (39.06)
III	40 (66.67)	39 (60.94)

Full Size Table

Citation: Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569
URL: https://www.wjgnet.com/1948-9366/full/v18/i3/114569.htm
DOI: https://dx.doi.org/10.4240/wjgs.v18.i3.114569

Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569 [DOI: 10.4240/wjgs.v18.i3.114569]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.